Phase 1 N=18 A Study on the Effects of Repeat Doses of Intraject® Sumatriptan on Local Site Signs
Healthy
Primary: The Number of Injections With Local Site Reactions (Bleeding, Swelling, Bruising and Erythema). — 0; 51; 0; 0 injections
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=57 Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival
Age-related Macular Degeneration · Central Retinal Vein Occlusion · Diabetic Macular Edema
Primary: Number of Participants Who Preferred Subconjunctival Anesthetic at the Third Follow-up Visit — 50 participants
Phase 4 N=984 Inactivated Influenza Via Jet Injection
Influenza, Human
Primary: Anti Influenza Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT) — 3.80; 3.77; 5.72; 5.70 Titers
Phase 3 N=222 A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma
Multiple Myeloma
Primary: Number of Patients With Overall Response (Complete Response + Partial Response) — 61; 31 Participants — p=0.00201
Phase 4 N=129 Topical Antibiotics and Intravitreous Injections
Intravitreous · Injections
Primary: Positive Culture — 8 percentage of patients
Phase 2 N=128 Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Primary: Percentage of Relapse Free Subjects (no Relapse) — 56.8; 59.5; 68.3; 43.2 percentage of participants — p=0.221
Phase 4 N=30 Vapocoolant Spray Used Prior to Intravenous (IV) Insertions
Pain
Primary: Pain Scale Using Visual Analog Scale — 1.13; 1.60 score on a scale
Phase 4 N=57 IV Iron Safety: Evaluation of Iron Species in Healthy Subjects
Anemia
Primary: Non-transferrin Bound Iron — 56230; 61250 ppb x hours
Phase 4 N=4 Subcutaneous vs. Intramuscular Testosterone
Testosterone Deficiency · Hypogonadism, Male
Primary: Change in Levels of Serum Total Testosterone Concentration — NA; 1043.6; NA; 785.7 ng/dl
Phase 4 N=1,250 Jet Injection for Influenza
Influenza, Human
Primary: Anti Influenza Type A/H1N1 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT) — 4.43; 4.38; 5.64; 5.64 Titers
N/A N=120 Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics
Bacterial Resistance
Primary: Number of Participants With Resistance of Ocular Flora to Commonly Used Post-injection Prophylactic Antibiotics — 10; 6 Participants
Phase 4 N=46 Control of Pain in Intravitreal Injections Using Topical NSAIDs
Intravitreal Injections · IVI
Primary: McGill Pain Questionnaire (SF-MPQ) Scores at Baseline — 0.62; 0.93; 0.53 score on a scale
Phase 3 N=50 Intravenous Fluid Therapy for the Treatment of Emergency Department Patients With Migraine Headache
Migraine Headache
Primary: Verbal Pain Score at 60 Minutes — 4.5; 4.9 units on a scale (0-10)
Phase 4 N=1,054 Oral Versus Intravenous Antibiotics for Bone and Joint Infections (OVIVA B&J)
Bone Infection · Joint Infection
Primary: The Frequency of Definite Failure of Infection Treatment. — 67; 74 Participants
Phase 3 N=45 Oral vs. Injectable Naltrexone for Hospitalized Veterans With Alcohol Dependence
Alcohol Dependence
Primary: Retention Rate: Percentage of Participants Attended an Initial Behavioral Treatment Visit Within 2 Weeks of Hospital Discharge. — 23; 22 Participants
Phase 4 N=62 Intravenous Sub-dissociative Dose Ketamine Injection Versus Infusion for Analgesia in the Emergency Department
Pain
Primary: Side Effects — 21; 25 Participants
N/A N=974 Isotonic Solution Administration Logistical Testing
Acute Kidney Injury
Primary: Proportion of Isotonic Crystalloid Which is 0.9% Saline — 91.2; 21.0 Percentage of fluid that was saline — p=0.001
Phase 4 N=58 Intravenous Fluids in Benign Headaches Trial
Headache
Primary: Reduction in Pain Scores at 60 Minutes — 48.7; 48.3 reduction in visual analog pain score
Phase 2 N=104 Intravenous Exenatide (Byetta) During Surgery
Euglycemia · Hypoglycemia · Hyperglycemia
Primary: The Primary Objective is to Determine the Ability of Intravenous Exenatide to: Maintain Intraoperative Euglycemia in Subjects With Initial Blood Glucose < 126 mg/dL in…
Phase 4 N=40 VENLID: The Application of a 10%-Lidocaine Spray Prior to the Insertion of a Peripheral Intra-venous Catheter in Female Adults
Pain
Primary: Pain Difference Caused by PIVC (Peripheral Intravenous Catheter) Rated by NRS (Numeric Rating Scale) Between Application of 10% Licocaine Spray and Placebo-for the…
Phase 2 N=45 Lidocaine Patches Prior to Intravenous Insertion
Need for Intravenous Catheter
Primary: Pain on Visual Analog Scale (VAS) — 18; 35 mm
N/A N=53 Does Intravenous Iron Therapy Decrease Serum Phosphorous Levels?
Chronic Renal Failure
Primary: Decrease in Serum Levels of Phosphorus in Patients After Treatment With Intravenous Iron. — 3.47 mg/dL
Phase 1 N=82 Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations
Diabetes · Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Injection Pain (VAS mm) — 20.0; 12.8; NA; NA mm
N/A N=243 Optical Detection of Intravenous Infiltration:A Pilot Study
Infiltration of Peripheral IV Therapy
Primary: Time Infiltration Detected by Nurse — 29.8; 32.3 hours
Phase 4 N=86 Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 42; 19; 25 Participants
Phase 4 N=65 Intraosseous Morphine in Primary TKA
Knee Disease · Arthritis Knee · Pain, Acute
Primary: Post-operative Pain — 4.29; 3.57 visual analog pain scale
Phase 2 N=81 Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia
Iron Deficiency · Fibromyalgia
Primary: Proportion of Patients With a ≥13 Point Improvement in FIQR Score — 30; 26 Participants
Phase 4 N=70 Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus
Type 1 Diabetes · Pregnancy, High Risk
Primary: Neonatal Hypoglycemia — 49.2; 50.1 mg/dL
N/A N=86 Safety and Effectiveness Clinical Evaluation of Injectable Medical Devices Viscol
Aesthetic Dermatology
Primary: Performance at 1 Month Investigator Overall VISCOL Range — 77 Participants — p=<0.0001
Phase 3 N=49 Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Primary Immunodeficiency Diseases (PID)
Primary: Ratio of Area Under the Concentration Curve (AUC 0-τ)/Week Following IV Administration to SC Administration of IGIV, 10% at an Adjusted/Individual Adapted Dose (Part…